Matching articles for "Vivitrol"

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • September 4, 2023;  (Issue 1684)
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)

   
The Medical Letter on Drugs and Therapeutics • September 4, 2023;  (Issue 1684)
...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e144-5 | Show Full IntroductionHide Full Introduction

Drugs for Alcohol Use Disorder

   
The Medical Letter on Drugs and Therapeutics • December 13, 2021;  (Issue 1639)
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called...
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Med Lett Drugs Ther. 2021 Dec 13;63(1639):193-8 | Show Full IntroductionHide Full Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • June 5, 2017;  (Issue 1522)
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of...
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the CDC, there were 33,091 deaths related to opioid overdose in the US in 2015, more than in any previous year. Several guidelines on the management of opioid use disorder have recently been published.
Med Lett Drugs Ther. 2017 Jun 5;59(1522):89-96 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)

   
The Medical Letter on Drugs and Therapeutics • June 5, 2017;  (Issue 1522)
...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2017 Jun 5;59(1522):e96-7 | Show Full IntroductionHide Full Introduction

Naltrexone (Vivitrol) - A Once Monthly Injection for Alcoholism

   
The Medical Letter on Drugs and Therapeutics • July 31, 2006;  (Issue 1240)
An injectable extended-release formulation of the opioid-receptor antagonist naltrexone (Vivitrol - Alkermes/Cephalon) has been approved by the FDA for once-monthly use, along with psychosocial support, to...
An injectable extended-release formulation of the opioid-receptor antagonist naltrexone (Vivitrol - Alkermes/Cephalon) has been approved by the FDA for once-monthly use, along with psychosocial support, to maintain abstinence from alcohol. Naltrexone inhibits the rewarding effects of alcohol. Oral naltrexone (Revia, and others) has been approved for treatment of alcohol dependence since 1994, but poor adherence has limited its effectiveness. In the new extended-release (XR) formulation, naltrexone is encapsulated in polylactide-co-glycolide microspheres (similar to absorbable suture material) and placed in aqueous suspension for intramuscular (IM) injection.
Med Lett Drugs Ther. 2006 Jul 31;48(1240):62-4 | Show Full IntroductionHide Full Introduction